The London Technology and Life Sciences team advised Sound Bioventures on its investment in the recent £19 million financing round of Theolytics. Sound Bioventures joins a strong existing investor syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford.
Theolytics is developing oncolytic viral therapy for the treatment of ovarian cancer. The financing will enable Theolytics to advance lead candidate THEO-260 through to clinical proof of concept.
Sound Bioventures is a venture capital fund investing in about-to-be clinical and clinical stage private companies in Europe and the USA developing novel medicines in specialty therapeutics areas. In conjunction with this financing, Thomas Tan, Principal at Sound Bioventures, will join Theolytics’ Board of Directors.
The Goodwin team was led by Sophie McGrath, Ben Taylor and Amie Corry.
For more details on the financing, please read the press release.